Invivyd, Inc. (IVVD)
NASDAQ: IVVD · Real-Time Price · USD
1.800
-0.100 (-5.26%)
At close: Mar 12, 2026, 4:00 PM EDT
1.779
-0.021 (-1.16%)
After-hours: Mar 12, 2026, 6:29 PM EDT
Revenue by Segment
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|
| Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
|---|
Discovery, Development and Commercialization of Antibody-Based Solutions | 53.43M | 25.38M | - | - | - | |
Discovery, Development and Commercialization of Antibody-Based Solutions Growth | 110.47% | - | - | - | - | |
| 53.43M | 25.38M | - | - | - | |
| 110.47% | - | - | - | - | |
Revenue by Geography
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|
| Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
|---|
| 53.43M | 25.38M | - | - | - | |
| 110.47% | - | - | - | - | |
| 53.43M | 25.38M | - | - | - | |
| 110.47% | - | - | - | - | |
Source: S&P Global Market Intelligence.
